Frown lines and wrinkles form as the muscle under the skin contracts. Over time, as your skin ages, these repeated expressions cause lasting impressions on your skin. Neurotoxins such as Xeomin or Botox are prescription medications that block the release of chemicals that cause these muscle contractions, causing these lines to soften, helping you look naturally refreshed and rejuvenated. Precise doses of Xeomin is administered into the muscles that contribute to the formation of lines and wrinkles. It works by blocking the neurotransmitter from the nerve endings, resulting in relaxed and minimized lines and wrinkles.
Xeomin works the same way to treat TMJ, grinding, and clenching, by weakening the overactive muscles that cause these problems.
Migraine and tension headaches have also been shown to decrease significantly following wrinkle relaxer injections. Studies have even confirmed improvements in depression, in addition to overall mood and feeling of well being as a result of wrinkle relaxers.
Xeomin typically lasts 3-6 months, and in some cases even longer.
XEOMIN® Product Description
XEOMIN® (incobotulinumtoxinA) is a prescription medication used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
XEOMIN® contains botulinum toxin type A, a protein purified from the bacterium Clostridium botulinum.
Botulinum toxin type A acts on nerve endings in muscles to prevent muscle fibers from contracting. By reducingthese contractions, XEOMIN® can temporarily reduce the lines on your forehead between your brows.
XEOMIN® was approved by the US Food and Drug Administration (FDA) in July 2011. It is now widely available to patients across the US.
BEFORE AND AFTER AT MAXIMUM FROWN*
*Individual results may vary.
Unretouched photos. The median first onset of XEOMIN® effect occurs within 7 days of injection. Maximum effect typically occurs at 30 days. The typical duration of effect is up to 3 months, but may last significantly longer or shorter in individual patients. In studies XEOMIN® treated subjects ranged from 24 to 74 years of age with an average age of 46.